Raphael Pharmaceutical (RAPH) Change in Account Payables (2020 - 2025)
Raphael Pharmaceutical's (RAPH) quarterly Change in Account Payables came in at $291000.0 in Q4 2025, up 171.85% year-over-year from $107043.6 in Q4 2024, and up 52.36% quarter-over-quarter from $191000.0 in Q3 2025.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Change in Account Payables (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical has disclosed Change in Account Payables across 6 years of filings, most recently posting $291000.0 for Q4 2025.
- In Q4 2025, Change in Account Payables rose 171.85% year-over-year to $291000.0; the TTM figure through Dec 2025 stood at $818000.0 (up 330.53% YoY), while the FY2025 annual figure was $818000.0, up 330.53% from the prior year.
- Change in Account Payables came in at $291000.0 for Q4 2025 at Raphael Pharmaceutical, up from $191000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $421000.0 in Q3 2023 to a low of -$405000.0 in Q4 2024.
- Average Change in Account Payables over 5 years is $68950.0, with a median of $60000.0 recorded in 2022.
- Year-over-year, Change in Account Payables slumped 10300.0% in 2023 and soared 831.58% in 2025.
- Over 5 years, Change in Account Payables stood at $94000.0 in 2021, then tumbled by 34.04% to $62000.0 in 2022, then sank by 448.39% to -$216000.0 in 2023, then sank by 87.5% to -$405000.0 in 2024, then jumped by 171.85% to $291000.0 in 2025.
- Per Business Quant data, the three most recent Change in Account Payables figures were $291000.0 in Q4 2025, $191000.0 in Q3 2025, and $278000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -70.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 18.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -66.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -8.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 7.11 Mn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 291,000.00 |
| Sep 30, 2025 | 191,000.00 |
| Jun 30, 2025 | 278,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Dec 31, 2024 | -405,000.00 |
| Sep 30, 2024 | 249,000.00 |
| Jun 30, 2024 | -38,000.00 |
| Mar 31, 2024 | 384,000.00 |
| Dec 31, 2023 | -216,000.00 |
| Sep 30, 2023 | 421,000.00 |
| Jun 30, 2023 | -102,000.00 |
| Mar 31, 2023 | -68,000.00 |
| Dec 31, 2022 | 62,000.00 |
| Sep 30, 2022 | 106,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Mar 31, 2022 | -67,000.00 |
| Dec 31, 2021 | 94,000.00 |
| Sep 30, 2021 | 131,000.00 |
| Jun 30, 2021 | -18,000.00 |
| Mar 31, 2021 | 27,000.00 |